Holocene Advisors, LP Morphic Holding, Inc. Transaction History

Holocene Advisors, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$34.33 - $62.11 $7.93 Million - $14.3 Million	230,919 Added 37.3%	849,951 $48.7 Million
Q1 2023 May 15, 2023	SELL	$26.01 - $48.69 $6.41 Million - $12 Million	-246,598 Reduced 28.49%	619,032 $23.3 Million
Q4 2022 Feb 14, 2023	SELL	$24.14 - $30.37 $8.63 Million - $10.9 Million	-357,508 Reduced 29.23%	865,630 $23.2 Million
Q3 2022 Nov 14, 2022	BUY	$22.23 - $33.37 $3.29 Million - $4.93 Million	147,777 Added 13.74%	1,223,138 $34.6 Million
Q2 2022 Aug 15, 2022	BUY	$19.74 - $43.01 $5.8 Million - $12.6 Million	293,619 Added 37.56%	1,075,361 $23.3 Million
Q1 2022 May 16, 2022	BUY	$36.25 - $52.02 $16.2 Million - $23.3 Million	447,177 Added 133.66%	781,742 $31.4 Million
Q4 2021 Feb 14, 2022	BUY	$43.27 - $65.72 $3.25 Million - $4.93 Million	75,031 Added 28.91%	334,565 $15.9 Million
Q3 2021 Nov 15, 2021	BUY	$53.61 - $67.5 $13.9 Million - $17.5 Million	259,534 New	259,534 $14.7 Million

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Holocene Advisors, LP, based on Form 13F filings with the SEC.

Stay updated on Holocene Advisors, LP with notifications on news.